View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
March 24, 2022updated 28 Mar 2022 5:49am

UK accounts for 3.8% share of global clinical trial activity in 2021

By Carmen

The UK has accounted for a 3.8% share of the global clinical trials activity in 2021, registering a decrease when compared with the last ten-year average of a 5.8% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in UK

Industry sponsored trials held an 86.4% share of all the clinical trials in the UK in 2021, when compared with the ten-year average of 81.5%. Non-industry sponsored trials accounted for a 13.6% share in 2021 as against the average of 18.5% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in UK

Oncology was the leading therapy area for industry sponsored clinical trials in the UK in 2021 with a 29.6% share, as against a five-year average of 31.4% and a ten-year average of 30.6%.

Central Nervous System held a 13.0% share in 2021, over a five-year average of 12.6% and a ten-year average of 12.6%.

Infectious Disease held an 11.1% share in 2021, compared to a five-year average of 9.7% and a ten-year average of 10.3%. Respiratory held an 8.4% share in 2021, as against a five-year average of 8.2% and a ten-year average of 8.7%.

Immunology held an 8.1% share, over a five-year average of 7.3% and a ten-year average of 7.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in UK

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in the UK in 2021 with a 32.8% share, as against a five-year average of 15.1% and a ten-year average of 15.5%.

Central Nervous System held a 16.8% share in 2021, over a five-year average of 21.6% and a ten-year average of 22.3%.

Oncology held a 16.0% share in 2021, compared to a five-year average of 12.7% and a ten-year average of 16.0%. Cardiovascular held a 14.5% share in 2021, as against a five-year average of 15.6% and a ten-year average of 17.5%.

Musculoskeletal Disorders held an 8.4% share, over a five-year average of 7.0% and a ten-year average of 6.0%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead industry sponsored clinical trials in UK in 2021

Phase II trials held a 38.4% share of industry sponsored clinical trials in the UK in 2021, over a five-year average of 38.5% and a ten-year average of 36.3%.

Phase III trials held a 37.4% share in 2021, as against a five-year average of 36.0% and a ten-year average of 35.9%. Phase I trials held a 17.9% share in 2021, compared to a five-year average of 18.4% and a ten-year average of 18.7%.

Phase IV trials held a 6.3% share in 2021, over a five-year average of 7.0% and a ten-year average of 9.2%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in UK in 2021

Phase II trials held a 50.4% share of non-industry sponsored clinical trials in the UK in 2021, over a five-year average of 51.1% and a ten-year average of 45.6%.

Phase III trials held a 23.7% share in 2021, as against a five-year average of 16.6% and a ten-year average of 17.4%. Phase IV trials held a 14.5% share, compared to a five-year average of 24.4% and a ten-year average of 28.9%.

Phase I held an 11.5% share in 2021, over a five-year average of 7.9% and a ten-year average of 8.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena